dAurAB2
Based on 1 Customer Validation
dAurAB2 is a potent Aurora-A/Aurora-B PROTAC degrader with DC50 values of 59 nM and 39 nM, respectively. dAurAB2 induces ubiquitination and proteasomal degradation of Aurora-A kinase and Aurora-B kinase, and indirectly reduces N-Myc protein levels. dAurAB2 can be used in studies related to neuroblastoma.
(Pink: Aurora A and Aurora B ligand (HY-10804); Blue: Cereblon ligand (HY-103597); Black: linker (HY-W105740)).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.61%
- CAS No.: 3115765-38-0
- Formule: C52H62BrN11O8
- Masse moléculaire:1049.02
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform PROTACs
MoreVoir tous les produits spécifiques à Isoform Aurora Kinase
More
Activité biologique
|
Aurora-A 59 nM (DC50) |
Aurora-B 39 nM (DC50) |
N-Myc |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| IMR-32 | DC50 |
59 nM
|
Aurora-A protein degradation potency in MYCN-amplified, TP53-WT IMR32 neuroblastoma cells assessed by western blotting after 24 h incubation.
Aurora-A protein degradation potency in MYCN-amplified, TP53-WT IMR32 neuroblastoma cells assessed by western blotting after 24 h incubation.
|
40785977 |
| IMR-32 | DC50 |
39 nM
|
Aurora-B protein degradation potency in MYCN-amplified, TP53-WT IMR32 neuroblastoma cells assessed by western blotting after 24 h incubation.
Aurora-B protein degradation potency in MYCN-amplified, TP53-WT IMR32 neuroblastoma cells assessed by western blotting after 24 h incubation.
|
40785977 |
dAurAB2 (10-1000 nM; 24 h) induces dose-dependent degradation of Aurora-A and Aurora-B in IMR32 cells, with DC50 values of 59 nM and 39 nM respectively, and downregulates N-Myc levels[1].
dAurAB2 (200 nM; 6 h) exhibits excellent overall selectivity, significantly reduces the abundance of Aurora-A, and shows extremely low off-target effects in MYCN-amplified Kelly neuroblastoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:IMR32 cells
-
Concentration:10, 50, 100, 200, 500, 1000 nM
-
Incubation Time:24 h
-
Result:Significantly degraded Aurora-A and Aurora-B, and downregulated N-Myc protein levels.
Chemical Information
-
CAS No. 3115765-38-0
-
Appearance Solid
-
Masse moléculaire 1049.02
-
Formule C52H62BrN11O8
-
Color Light yellow to yellow
-
SMILES
O=C(NCCCCCCCCCCCC(N1CCN(C2=CC=C(C3=NC4=C(N5CCN(CC6=NOC(C)=C6)CC5)C(Br)=CN=C4N3)C=C2)CC1)=O)COC7=CC=CC(C(N8C(CC9)C(NC9=O)=O)=O)=C7C8=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (95.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (269 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Nelson SE, et al. Development of Dual Aurora-A and Aurora-B Degrading PROTACs for -Amplified Neuroblastoma. ChemMedChem. 2025 Mar 03;20(5):e202400703. [Content Brief]
[2]. Pogash S, et al. Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation. RSC medicinal chemistry. 2025 Jul 16;16(7):2958-2973. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9533 mL | 4.7664 mL | 9.5327 mL | 23.8318 mL |
| 5 mM | 0.1907 mL | 0.9533 mL | 1.9065 mL | 4.7664 mL | |
| 10 mM | 0.0953 mL | 0.4766 mL | 0.9533 mL | 2.3832 mL | |
| 15 mM | 0.0636 mL | 0.3178 mL | 0.6355 mL | 1.5888 mL | |
| 20 mM | 0.0477 mL | 0.2383 mL | 0.4766 mL | 1.1916 mL | |
| 25 mM | 0.0381 mL | 0.1907 mL | 0.3813 mL | 0.9533 mL | |
| 30 mM | 0.0318 mL | 0.1589 mL | 0.3178 mL | 0.7944 mL | |
| 40 mM | 0.0238 mL | 0.1192 mL | 0.2383 mL | 0.5958 mL | |
| 50 mM | 0.0191 mL | 0.0953 mL | 0.1907 mL | 0.4766 mL | |
| 60 mM | 0.0159 mL | 0.0794 mL | 0.1589 mL | 0.3972 mL | |
| 80 mM | 0.0119 mL | 0.0596 mL | 0.1192 mL | 0.2979 mL |
dAurAB2 Related Classifications
HY-171769 Related Classifications
Powered by Bioz